Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical control
Authors:
- Gert O. De MeerleerGMGert O. De Meerleer
- Valérie H. FonteyneVFValérie H. Fonteyne
- Luc VakaetLVLuc Vakaet
- Geert M. VilleirsGVGeert M. Villeirs
- Ludwig DenoyetteLDLudwig Denoyette
- Antony VerbaeysAVAntony Verbaeys
- Nicolas LummenNLNicolas Lummen
- Wilfried J. De NeveWNWilfried J. De Neve
- 1 February 2007
- journal article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 82 (2) , 160-166
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effectsBritish Journal of Cancer, 2005
- The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: Feasibility and acute toxicityInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Intensity-modulated radiotherapy as primary treatment for prostate cancer: Acute toxicity in 114 patientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- The Incidence of Inclusion of the Sigmoid Colon and Small Bowel in the Planning Target Volume in Radiotherapy for Prostate CancerStrahlentherapie und Onkologie, 2004
- Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen eraCancer, 2002
- An anatomy-based beam segmentation tool for intensity-modulated radiation therapy and its application to head-and-neck cancer.International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001
- Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparisonInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and GoserelinNew England Journal of Medicine, 1997
- Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of 4–20 ng/mlInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995